Immunotherapy combination ‘new standard of care’ in metastatic renal cell carcinoma – Healio
|
Immunotherapy combination 'new standard of care' in metastatic renal cell carcinoma
Healio MIAMI — The combination of ipilimumab and nivolumab is an effective standard frontline treatment of patients with metastatic renal cell carcinoma, according to results from the Checkmate-214 trial presented at the International Kidney Cancer Symposium. |
